168 related articles for article (PubMed ID: 31728517)
1. Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis.
Liauw SL; Ham SA; Das LC; Rudra S; Packiam VT; Koshy M; Weichselbaum RR; Becker YT; Bodzin AS; Eggener SE
J Natl Cancer Inst; 2020 Aug; 112(8):847-854. PubMed ID: 31728517
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer in kidney transplant recipients - a nationwide register study.
Bratt O; Drevin L; Prütz KG; Carlsson S; Wennberg L; Stattin P
BJU Int; 2020 May; 125(5):679-685. PubMed ID: 31955497
[TBL] [Abstract][Full Text] [Related]
3. Impact of serious mental illness on the treatment and mortality of older patients with locoregional high-grade (nonmetastatic) prostate cancer: retrospective cohort analysis of 49 985 SEER-Medicare patients diagnosed between 2006 and 2013.
Fried DA; Sadeghi-Nejad H; Gu D; Zhou S; He W; Giordano SH; Pentakota SR; Demissie K; Helmer D; Shen C
Cancer Med; 2019 May; 8(5):2612-2622. PubMed ID: 30945473
[TBL] [Abstract][Full Text] [Related]
4. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.
Dess RT; Hartman HE; Mahal BA; Soni PD; Jackson WC; Cooperberg MR; Amling CL; Aronson WJ; Kane CJ; Terris MK; Zumsteg ZS; Butler S; Osborne JR; Morgan TM; Mehra R; Salami SS; Kishan AU; Wang C; Schaeffer EM; Roach M; Pisansky TM; Shipley WU; Freedland SJ; Sandler HM; Halabi S; Feng FY; Dignam JJ; Nguyen PL; Schipper MJ; Spratt DE
JAMA Oncol; 2019 Jul; 5(7):975-983. PubMed ID: 31120534
[TBL] [Abstract][Full Text] [Related]
5. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
6. Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer.
Xiang M; Nguyen PL
Brachytherapy; 2015; 14(6):773-80. PubMed ID: 26489921
[TBL] [Abstract][Full Text] [Related]
7. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act.
Mahal BA; Aizer AA; Ziehr DR; Hyatt AS; Lago-Hernandez C; Chen YW; Choueiri TK; Hu JC; Sweeney CJ; Beard CJ; D'Amico AV; Martin NE; Trinh QD; Nguyen PL
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):273-9. PubMed ID: 24980272
[TBL] [Abstract][Full Text] [Related]
8. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
9. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
[TBL] [Abstract][Full Text] [Related]
10. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
11. Lung Cancer Prognosis in Elderly Solid Organ Transplant Recipients.
Sigel K; Veluswamy R; Krauskopf K; Mehrotra A; Mhango G; Sigel C; Wisnivesky J
Transplantation; 2015 Oct; 99(10):2181-9. PubMed ID: 25839704
[TBL] [Abstract][Full Text] [Related]
12. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.
Yang DD; Muralidhar V; Nguyen PL; Buzurovic I; Martin NE; Mouw KW; Devlin PM; Trinh QD; Orio PF; King MT
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):904-911. PubMed ID: 29063853
[TBL] [Abstract][Full Text] [Related]
13. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
14. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
[TBL] [Abstract][Full Text] [Related]
15. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
16. Recreational Physical Activity in Relation to Prostate Cancer-specific Mortality Among Men with Nonmetastatic Prostate Cancer.
Wang Y; Jacobs EJ; Gapstur SM; Maliniak ML; Gansler T; McCullough ML; Stevens VL; Patel AV
Eur Urol; 2017 Dec; 72(6):931-939. PubMed ID: 28711382
[TBL] [Abstract][Full Text] [Related]
17. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
18. Independent and Joint Effects of Testosterone Replacement Therapy and Statins use on the Risk of Prostate Cancer Among White, Black, and Hispanic Men.
Lopez DS; Polychronopoulou E; Tsilidis KK; Khera M; Su LJ; Fowke JH; Peek MK; Kuo YF; Markides K; Canfield S
Cancer Prev Res (Phila); 2021 Jul; 14(7):719-728. PubMed ID: 33879532
[TBL] [Abstract][Full Text] [Related]
19. Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis.
Muralidhar V; Mahal BA; Nguyen PL
Radiat Oncol; 2015 Jul; 10():155. PubMed ID: 26220664
[TBL] [Abstract][Full Text] [Related]
20. Commentary on "initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer." Aizer AA, Chen MH, Hattangadi J, D'Amico AV. Harvard Radiation Oncology program, Boston, MA.: BJU Int 2013. doi: 10.1111/j.1464-410X.2012.11789.x. [Epub ahead of print].
Ritter MA
Urol Oncol; 2014 Feb; 32(2):208-9. PubMed ID: 24445289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
